The new lineage called B.1.618 is distinct from the B.1.617, also known as the 'double mutant' virus that contains two mutations, E484Q and L245R, and is believed to be behind the powerful second COVID-19 wave sweeping through India.
According to medical practitioners, the treatment is especially useful in controlling disease among those who have not received the vaccine or got only one shot and also the high-risk contacts of a patient.
'People who have already got diabetes or heart disease or high blood pressure seem to be more badly affected by the disease.'
The B.1.640.2 variant has been reported by researchers at institute IHU Mediterranee Infection in at least 12 cases, and has been linked to travel to African country Cameroon.
Intake of nutrient-rich foods is crucial.
The study describes a new blood test which pinpoints the immune system molecules called antibodies in infected individuals that specifically target a unique piece of the novel coronavirus SARS-CoV-2's spike protein.
The Australian immunologist, who cautioned that the number of COVID-19 cases will rise in the coming days, said the earliest time frame for an effective vaccine 'going into large numbers of people' is nine to 12 months.
Cancer cells thrive in acidic environments.
... 'Or any country which has reasonable vaccine coverage.' 'The emergence of Omicron clearly proves that if we allow a virus to circulate in an unvaccinated population, it would take a form which could be a Variant of Concern, or a new variant.'
Scientists have identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the SARS illness.
Advocate Abbad Ponda, his lawyer, said a person with low immunity is easily susceptible to catching coronavirus.
Pfizer can show the FDA approval to the Indian regulator and present a case that based on whatever data submitted, the US regulator has granted a full marketing nod, says Sohini Das.
'There is little doubt that India's tobacco epidemic is contributing to its TB epidemic,' says Neil W Schluger.
While some reports claim the mutation is capable of enhancing the infectivity of the virus, this is not well established and also does not necessarily indicate more virulence or harmfulness of the disease.
'If our body is able to mount a very successful immune response, we can negate the virus.'
Arthi Raghuram, founder of Deyga Organics shares simple tips to keep your skin healthy.
The therapy uses T-cells, which are the immune system's major line of defense against tumors
The phase 3 trial findings indicate that Covaxin induces a robust antibody response with no severe vaccine-related adverse events or deaths reported among the trial participants, the authors of the study said.
E-cigarettes pose a huge health risk to users, who more often than not are adolescents and young adults
'The reality of this virus is that as long as it is circulating, it can mutate into new variants and by the time you realise that this is a new virus, which is more dangerous, and more transmissible, it is too late.'
Investing in your wellness shows that you honour and love yourself, says Lifestyle Coach Shivli Bembey.
'A good 30 per cent of people will still get infected after getting the Covishield vaccine.'
Can Interferon alfa-2b treat COVID-19 effectively?
'At the stage where we are in today in the country, by the time mass vaccination becomes available, it would be around the middle of next year.' 'Most of those people, who got infected this year, will be next year back to level zero -- once again susceptible.'
'Vigilance is the enemy of the virus.' 'We need to be alert all the time, about this, until we fully understand it.' 'And that's going to take years, actually.'
A guide to post-COVID care to be followed at home.
Coronaviruses, like other RNA viruses, can develop mutations in three different ways: by mistake from copying errors during viral replication, through interactions with other viruses infecting the same cell, or they can be induced by RNA modification systems which are part of host immunity, the researchers explained.
The study noted that humans are not protected from the G4 virus by the immunity offered by other human influenza vaccine strains, indicating that there is no preexisting population immunity to the virus.
'Prevention plus vaccination is what is going to take us into better territory by September or October.'
Scientists have developed an HIV test which they claim works in just 30 minutes and can be performed anywhere in the world -- no laboratory required.
The study also shows that levels of these antibodies that are able to recognise and fight the virus are lower with increasing age, and that levels decline over time, providing additional evidence in support of plans to deliver a booster dose to vulnerable people.
Researchers at the University of Georgia Cancer Center have developed a carbohydrate-based vaccine, that in mice has effectively produced a strong immune response to cancer cells.
Over time, as more mutations occur, the vaccine may need to be altered.
'The most intriguing thing (about COVID-19) is the range of the illness -- from asymptomatic or less symptoms to death and quite severe manifestations.' 'The vaccine will be at least another year away from having any effect.'
'Even after vaccines are given, precautions like using a mask and maintaining social distancing have to be taken.'
'Mortality or hospitalisation has not increased in South Africa because of the new variant.' 'There is nothing to show so far that it is more infectious.' 'I am of the opinion that at the moment, there is no reason to panic.'
This summer replace that extra mango with a musk melon and see the healthy magic it creates.
Healthy food = healthy mind and body.
'SARS-CoV-2 is going to change to avoid/overcome any thing thrown at it.'
A steady decline in new COVID-19 cases has been recorded in India for the last 20 days, with 24 states witnessing a dip in active cases since the last week, the Union health ministry said.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances